SELLAS Life Sciences Group, Inc.
(NASDAQ : GALE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
VTLVital Therapies, Inc.
1.50%13.513.3%$792.68m
AMGNAmgen Inc.
2.36%204.021.3%$749.47m
GILDGilead Sciences, Inc.
0.43%63.140.9%$384.23m
CELGCelgene Corporation
1.53%94.741.3%$360.74m
ILMNIllumina, Inc.
0.49%286.173.5%$321.19m
BIIBBiogen Inc.
1.78%231.681.3%$305.34m
VRTXVertex Pharmaceuticals Incorporated
2.11%184.941.9%$260.38m
EXASExact Sciences Corporation
1.35%119.8224.1%$245.81m
ALXNAlexion Pharmaceuticals, Inc.
1.66%110.852.0%$238.74m
REGNRegeneron Pharmaceuticals, Inc.
1.28%296.852.6%$212.35m
AAgilent Technologies, Inc.
2.18%71.111.6%$206.33m
SRPTSarepta Therapeutics, Inc.
2.44%124.9514.7%$156.17m
INCYIncyte Corporation
3.11%83.122.5%$97.22m
BMRNBioMarin Pharmaceutical Inc.
6.65%76.504.3%$91.98m
SGENSeattle Genetics, Inc.
3.25%79.206.5%$90.21m

Company Profile

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.